首页> 外文期刊>Mutation Research: International Journal on Mutagenesis, Chromosome Breakage and Related Subjects >Automated human blood micronucleated reticulocyte measurements for rapid assessment of chromosomal damage.
【24h】

Automated human blood micronucleated reticulocyte measurements for rapid assessment of chromosomal damage.

机译:自动化人血微核网织红细胞测量,可快速评估染色体损伤。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

This study evaluated the utility of human blood micronucleated reticulocyte (MNCD71+) frequency measurement as a cytogenetic damage biomarker. The analytical methodology was flow cytometry in conjunction with a previously described three color fluorescence labeling technique that includes anti-CD71 to focus analyses on the most immature fraction of reticulocytes [S.D. Dertinger, K. Camphausen, J.T. MacGregor, M.E. Bishop, D.K. Torous, S. Avlasevich, et al., Three-color labeling method for flow cytometric measurement of cytogenetic damage in rodent and human blood, Environ. Mol. Mutagen. 44 (2004) 427-435]. Blood specimens from 50 self-reported healthy adult volunteers were studied. In addition to MNCD71+ measurements, blood plasma folate and B12 levels were assessed, since these variables tend to influence other indices of cytogenetic damage. Time-course data are also provided for 10 cancer patients undergoing treatment. For these subjects, frequency of MNCD71+ was measured immediately before therapy, and daily during the first week of chemotherapy and/or fractionated radiotherapy. For the group of healthy volunteers, the variables of age, and folate and B12 levels demonstrated no significant effect on MNCD71+ frequency. In addition, no difference was observed between pre-treatment MNCD71+ values for cancer patients compared with healthy volunteers. Regarding chemotherapy and/or partial body radiotherapy, elevated frequencies were observed upon initiation of treatment for 9 of the 10 patients studied. Maximal effects were observed 3-5 days following initiation of therapy. The largest increases in frequency of MNCD71+ (up to 25.9-fold) were observed in those patients exposed to anti-neoplastic drugs, presumably due to the systemic red marrow exposure provided by these agents. Taken together, these data support the hypothesis that the MNCD71+ endpoint represents a valuable biomarker of cytogenetic damage that does not require cell culture or microscopy-based scoring.
机译:这项研究评估了人类血液微核网织细胞(MNCD71 +)频率测量作为细胞遗传损伤生物标志物的实用性。分析方法是流式细胞术结合先前描述的三色荧光标记技术,该技术包括抗CD71,以将分析重点放在网状细胞的最不成熟部分上。 Dertinger,K.Camphausen,J.T.麦格雷戈(McEreg Bishop) Torous,S.Avlasevich等人,``三色标记方法,用于流式细胞术测量啮齿动物和人类血液中的细胞遗传学损伤'',Environ。大声笑诱变剂。 44(2004)427-435]。研究了来自50位自我报告的健康成人志愿者的血液样本。除了测量MNCD71 +外,还评估了血浆叶酸和B12水平,因为这些变量往往会影响其他细胞遗传学损伤指标。还提供了10位接受治疗的癌症患者的时程数据。对于这些受试者,在治疗前即刻和化疗和/或分级放疗的第一周中每天测量MNCD71 +的频率。对于健康志愿者组,年龄,叶酸和B12水平的变量对MNCD71 +频率无明显影响。此外,与健康志愿者相比,癌症患者的治疗前MNCD71 +值之间没有差异。关于化学疗法和/或部分身体放疗,研究开始的10名患者中有9名在开始治疗时观察到频率升高。开始治疗后3-5天观察到最大效果。在那些接受抗肿瘤药物治疗的患者中,MNCD71 +的出现频率增加最多(最多25.9倍),这可能是由于这些药物提供的全身性红骨髓暴露所致。综上所述,这些数据支持以下假设:MNCD71 +终点代表了细胞遗传学损伤的宝贵生物标志物,不需要细胞培养或基于显微镜的评分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号